Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Coherus Oncology Inc
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
Find out what a historical investment in Coherus Oncology Inc would be worth today using our CHRS stock calculator.
Market Capitalisation
$228.29M
Price-earnings ratio
-
Dividend yield
0.00%
Volume
701.96K
High today
$1.56
Low today
$1.47
Open price
$1.47
52-week high
$2.62
52-week low
$0.71
Ready to start your investing journey with Stake?
Open an accountHow do I buy CHRS shares in Australia?
Buying CHRS shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Coherus Oncology Inc in minutes.
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in CHRS
What is the ticker symbol of Coherus Oncology Inc?
The ticker symbol for Coherus Oncology Inc is CHRS.
How much is one share of CHRS?
One share of CHRS is valued at $1.52 as of 20 May 2026.
What is the market capitalisation of Coherus Oncology Inc CHRS?
As of 20 May 2026 Coherus Oncology Inc has a market cap of $228.29M.
What is the 52-week high for Coherus Oncology Inc stock?
The Coherus Oncology Inc 52-week high stock price is $2.62.
What is the 52-week low for Coherus Oncology Inc stock?
The Coherus Oncology Inc 52-week low stock price is $0.71.
Can I buy CHRS shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy CHRS shares and over 12,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in CHRS on Stake
- Buy CHRS from US$3 brokerage
- Invest in 9,500+ U.S. stocks and ETFs
- Own a slice of CHRS from only US$10 with fractional shares
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
CHRS related stocks